Zomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample Dilution
The TRUFORMA Platform now has the widest dynamic range (without manual dilution) available either at the Point of Care or from a Reference Lab
ANN ARBOR, MI / ACCESS Newswire / May 21, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ('Zomedica' or the 'Company'), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced an update to one of their fastest growing assays, insulin for equine plasma. This update increases the test's already industry-leading point of care dynamic range and adds a new function, automatic sample dilution, that allows a veterinarian to measure insulin at the highest levels with no additional steps or increase in time-to-result on the TRUFORMA In-Clinic Biosensor Testing Platform.
'When we introduced our equine insulin assay in October of 2024, one of the most frequent requests we received was for a dilution protocol to measure insulin level in horses suspected to be greater than 250 µU/mL,' said Ian Harmon, Senior Director, R&D. Ian continues, 'In response, rather than validating an external dilution protocol that would involve additional steps for the veterinarian and staff, our engineers designed a way to have the TRUFORMA device automatically dilute the sample for them and run the test with no additional time or steps. The user simply selects the 'Auto Dilute' option from the test menu screen, and the TRUFORMA device takes it from there. The uniqueness of our single-use test cartridges allows us this flexibility of design and is something that no other platform can do.'
By having the TRUFORMA device perform the dilution automatically on the existing test cartridge, consistency from test-to-test is assured and the staff is freed from having to perform a tedious additional task.
The Zomedica R&D team was also able to increase the already industry-leading dynamic range of the standard (or default, undiluted) in-clinic insulin test by 60%! The chart below illustrates the new dynamic ranges for both the default and auto dilute protocols, making the TRUFORMA insulin test for equine plasma the most dynamic test of its kind in the world.
T.J. Barclay, DVM, Senior Professional Services Veterinarian for Zomedica, commented, 'In recent years, insulin dysregulation in horses and ponies has been increasingly recognized as the most significant risk factor for developing laminitis. In the more severe cases, insulin levels may be above a test's upper limit of detection, rendering us unable to determine by serial monitoring if our treatment is effective. In those cases, quantifying extremely high insulin levels has required sending samples to a reference lab where they can perform sample dilutions. Having a device that gives us results in minutes at the point of care that has a both a high dynamic range by default and a process that dilutes the sample on demand covers all patient types we may encounter, helping us make quicker decisions during the treatment and monitoring process.'
With the increased dynamic range and new automatic dilution function, along with the consistency, accuracy, and convenience of the original assay, Zomedica has set a new standard for point of care equine insulin testing.
The TRUFORMA Insulin assay for equine plasma with automatic sample dilution may be ordered now from Zomedica. For more information, visit www.zomedica.com.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $65 million in liquidity as of March 31, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.
Follow Zomedica
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate' and other similar words, or statements that certain events or conditions 'may' or 'will' occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
[email protected]
1-734-369-2555
SOURCE: Zomedica Corp.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Opinion - It's hurricane season again, and public health hangs in the balance
June marks the beginning of the 2025 Atlantic hurricane season, and forecasters are warning of above-average activity. More than half of U.S. coastal areas should plan to face a major hurricane of Category 3, 4, or 5. If our 2024 experience is a reliable predictor, we can anticipate more than $100 billion in damage, more than 100 fatalities and an increasingly problematic, if overlooked, element of these disasters: the threat to public health. Hurricanes and other water-centric events, like flooding, are creating ideal environments for the transmission of infectious diseases, from mold exposure to flesh-eating diseases to mosquito-borne viruses. Clusters of a potentially fatal infection caused by Vibrio bacteria, which can cause severe diarrhea and necrotizing skin lesions, hit Florida after Hurricane Ian in 2023. Cases in 2024 exceeded that total, with high burdens in Florida counties that experienced the worst flooding from Hurricane Helene. In Texas last summer, health officials warned the public of the risk of contracting West Nile virus post-Hurricane Beryl. Mosquito-borne illness is possible wherever there are mosquitoes. Florida, California and Texas all experienced locally acquired cases of dengue fever in 2024. Chikungunya, which can result in lifelong physical debilitation, is also present in the United States, with travel-associated and locally acquired cases being documented in Gulf states as recently as 2019. Several deaths from Eastern equine encephalitis occurred last year in northeastern states, with several towns instituting curfews to curb the mosquito-borne threat. Rises in mosquito populations are a well-documented hazard after hydrologic disasters like hurricanes, tsunamis and floods. These events can compromise sewage pipes, contaminate drinking water and result in diffuse areas of standing water that become breeding grounds for mosquitoes. Emergency preparedness professionals have long understood the risk. What's changing is the frequency of billion-dollar disasters — and with them, we suspect, greater damage, flooding, and disease risk. The good news is that we can leverage past experience, predictive models and tools like state and regional medical stockpiles to mitigate some of the worst health impacts. By strategically positioning medical supplies and countermeasures closer to the point of need, health authorities can significantly reduce response time, minimize logistical challenges and save lives. A number of states already have medical stockpiles for basic medications and personal protective equipment; others are creating or updating legislative authorities for them. These stockpiles generally lack federal support and medical countermeasures for high-consequence threats. The utility of state or regional caches could be expanded to include emerging needs like vaccines, treatments and diagnostics for vector-borne infections. Congress authorized the Department of Health and Human Services to conduct a pilot program matched by local funds for state stockpiling of medical countermeasures and other supplies for public health emergencies. The Biden administration did not request funding for state stockpiles and Congress has not appropriated funds for the program, however, stagnating the initiative. Funding is the number one type of support that jurisdictions say they need to help them establish and maintain stockpiles. Investing in state or regional stockpiles is a cost-effective approach to emergency preparedness. It minimizes the need for last-minute, high-cost procurements during crises, places more autonomy in the hands of states and helps maintain health care system resilience. President Trump's executive order on preparedness recognizes ownership of preparedness at the state and local level, and calls on federal policy to help empower state and local jurisdictions to make smart infrastructure choices. This same ethos can extend to public health preparedness. Last year's final report of the congressional Select Subcommittee on the Coronavirus Pandemic concluded that state stockpiles can provide a tailored local complement to the federal Strategic National Stockpile. As natural disasters increase in frequency and intensity, the federal government can support local decision-makers in meeting their communities' unique public health readiness needs. During COVID-19, many local officials did not know what was in the federal stockpile. Drawing stockpiles closer to the communities that will need them, tied to input from local, state or regional medical advisory groups, would increase awareness of stockpile contents and enable tailored input to support assets these communities need. Redundancies built into state or regional caches could allow local health care providers access to critical supplies that allow them to meet medical standards of practice even in a crisis. State stockpiles could facilitate greater efficacy of vendor-managed inventories and improve the quality and efficiency of supply rotations. Especially for countermeasures that have cold chain requirements or other complicated logistics, the federal role can be to provide the training and best practices to allow jurisdictions to successfully store and distribute these assets when needed. COVID-19 revealed a national unpreparedness to increase production rationally based on identifiable gaps pre-disaster. For example, better local input on necessary ventilator functionalities would have improved the production of quality devices as demand surged, rather than devices produced by auto manufacturers that were failures. State and regional stockpiles can reverse this underpreparedness and empower local communities. Congress should show its federal support by extending the authorized timeline for the state stockpile program and, critically, funding it commensurately in the coming appropriations cycle. By strategically positioning medical supplies and countermeasures closer to the point of need, a federal-regional-state partnership can significantly reduce response time, minimize logistical challenges and save lives before future hurricane seasons and other regional disasters occur. Craig Vanderwagen is a former assistant secretary for preparedness and response in the Department of Health and Human Services and the founder and general manager of East West Protection, LLC, which provided private and public sector disaster preparedness support. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
42 minutes ago
- Yahoo
Crazy Discount Codes App Helps Shoppers Save Big with Curated Retail Deals
Mobile app simplifies deal hunting by delivering real-time discounts from top retailers-all in one easy-to-use platform. ATLANTA, GA / / June 13, 2025 / Shoppers looking to stretch their dollars now have a powerful new tool: Crazy Discount Codes, a mobile app that delivers the best retail discounts directly to their fingertips. The app curates real-time deals from top brands and retailers, eliminating the need to search multiple sites or clip coupons. Created with convenience in mind, Crazy Discount Codes offers an all-in-one destination for discovering verified deals across fashion, electronics, home essentials, and more. Users can effortlessly browse time-sensitive promotions from well-known stores-all within a clean, user-friendly interface. "I built this app because I know how frustrating it is to miss out on deals or waste time looking for discounts," said Elpagnier Williams, founder of Crazy Discount Codes. "This app brings together the best offers and saves people both time and money." Now available on the App Store and Google Play, Crazy Discount Codes is already gaining traction among everyday shoppers and savvy savers alike. Whether you're browsing for essentials or exploring weekend sales, this app ensures you never miss a chance to save. About Crazy Discount Codes Crazy Discount Codes is a mobile savings platform that curates the latest retail discounts from major brands. Designed for smart shoppers, the app delivers verified deals in a clean, easy-to-use mobile experience. Learn more and download the app: Download on the App StoreDownload on Google Play Contact Information Elpagnier Williams Founder, Crazy Discount Codesads@ SOURCE: Crazy Discount Codes View the original press release on ACCESS Newswire
The Hill
3 hours ago
- The Hill
It's hurricane season again, and public health hangs in the balance
June marks the beginning of the 2025 Atlantic hurricane season, and forecasters are warning of above-average activity. More than half of U.S. coastal areas should plan to face a major hurricane of Category 3, 4, or 5. If our 2024 experience is a reliable predictor, we can anticipate more than $100 billion in damage, more than 100 fatalities and an increasingly problematic, if overlooked, element of these disasters: the threat to public health. Hurricanes and other water-centric events, like flooding, are creating ideal environments for the transmission of infectious diseases, from mold exposure to flesh-eating diseases to mosquito-borne viruses. Clusters of a potentially fatal infection caused by Vibrio bacteria, which can cause severe diarrhea and necrotizing skin lesions, hit Florida after Hurricane Ian in 2023. Cases in 2024 exceeded that total, with high burdens in Florida counties that experienced the worst flooding from Hurricane Helene. In Texas last summer, health officials warned the public of the risk of contracting West Nile virus post-Hurricane Beryl. Mosquito-borne illness is possible wherever there are mosquitoes. Florida, California and Texas all experienced locally acquired cases of dengue fever in 2024. Chikungunya, which can result in lifelong physical debilitation, is also present in the United States, with travel-associated and locally acquired cases being documented in Gulf states as recently as 2019. Several deaths from Eastern equine encephalitis occurred last year in northeastern states, with several towns instituting curfews to curb the mosquito-borne threat. Rises in mosquito populations are a well-documented hazard after hydrologic disasters like hurricanes, tsunamis and floods. These events can compromise sewage pipes, contaminate drinking water and result in diffuse areas of standing water that become breeding grounds for mosquitoes. Emergency preparedness professionals have long understood the risk. What's changing is the frequency of billion-dollar disasters — and with them, we suspect, greater damage, flooding, and disease risk. The good news is that we can leverage past experience, predictive models and tools like state and regional medical stockpiles to mitigate some of the worst health impacts. By strategically positioning medical supplies and countermeasures closer to the point of need, health authorities can significantly reduce response time, minimize logistical challenges and save lives. A number of states already have medical stockpiles for basic medications and personal protective equipment; others are creating or updating legislative authorities for them. These stockpiles generally lack federal support and medical countermeasures for high-consequence threats. The utility of state or regional caches could be expanded to include emerging needs like vaccines, treatments and diagnostics for vector-borne infections. Congress authorized the Department of Health and Human Services to conduct a pilot program matched by local funds for state stockpiling of medical countermeasures and other supplies for public health emergencies. The Biden administration did not request funding for state stockpiles and Congress has not appropriated funds for the program, however, stagnating the initiative. Funding is the number one type of support that jurisdictions say they need to help them establish and maintain stockpiles. Investing in state or regional stockpiles is a cost-effective approach to emergency preparedness. It minimizes the need for last-minute, high-cost procurements during crises, places more autonomy in the hands of states and helps maintain health care system resilience. President Trump's executive order on preparedness recognizes ownership of preparedness at the state and local level, and calls on federal policy to help empower state and local jurisdictions to make smart infrastructure choices. This same ethos can extend to public health preparedness. Last year's final report of the congressional Select Subcommittee on the Coronavirus Pandemic concluded that state stockpiles can provide a tailored local complement to the federal Strategic National Stockpile. As natural disasters increase in frequency and intensity, the federal government can support local decision-makers in meeting their communities' unique public health readiness needs. During COVID-19, many local officials did not know what was in the federal stockpile. Drawing stockpiles closer to the communities that will need them, tied to input from local, state or regional medical advisory groups, would increase awareness of stockpile contents and enable tailored input to support assets these communities need. Redundancies built into state or regional caches could allow local healthcare providers access to critical supplies that allow them to meet medical standards of practice even in a crisis. State stockpiles could facilitate greater efficacy of vendor-managed inventories and improve the quality and efficiency of supply rotations. Especially for countermeasures that have cold chain requirements or other complicated logistics, the federal role can be to provide the training and best practices to allow jurisdictions to successfully store and distribute these assets when needed. COVID-19 revealed a national unpreparedness to increase production rationally based on identifiable gaps pre-disaster. For example, better local input on necessary ventilator functionalities would have improved the production of quality devices as demand surged, rather than devices produced by auto manufacturers that were failures. State and regional stockpiles can reverse this underpreparedness and empower local communities. Congress should show its federal support by extending the authorized timeline for the state stockpile program and, critically, funding it commensurately in the coming appropriations cycle. By strategically positioning medical supplies and countermeasures closer to the point of need, a federal-regional-state partnership can significantly reduce response time, minimize logistical challenges and save lives before future hurricane seasons and other regional disasters occur. Craig Vanderwagen is a former assistant secretary for preparedness and response in the Department of Health and Human Services and the founder and general manager of East West Protection, LLC, which provided private and public sector disaster preparedness support.
